PMID: 6406071Mar 1, 1983Paper

Optimal routes of administration of ergotamine tartrate in cluster headache patients. A pharmacokinetic study

Cephalalgia : an International Journal of Headache
K EkbomE Waldenlind

Abstract

Bioavailability and rate of absorption of ergotamine were studied in eight cluster headache patients outside attacks. In a cross-over design, approximately 2 mg ergotamine tartrate was administered as effervescent tablets, suppositories, and from an inhalation device, with 0.25 mg intravenously as the reference. Ergotamine in plasma was measured by high performance liquid chromatography with fluorescence detection from 5 to 420 min. For all three routes of administration, a similar low (0.5-4.2%) bioavailability of ergotamine was estimated. Only inhalation of ergotamine resulted in early (at 5 min) peak concentrations of ergotamine in plasma and is therefore most likely to relieve the short-lived attacks of cluster headache. The inhalation route for ergotamine poses problems, however, and we suggest ways of improving the inhalation device.

References

Feb 19, 1979·European Journal of Clinical Pharmacology·V Ala-HurulaE Hokkanen
Nov 1, 1979·European Journal of Clinical Pharmacology·V Ala-HurulaE Hokkanen
Feb 1, 1975·Journal of Pharmacokinetics and Biopharmaceutics·J G Wagner
Aug 1, 1975·British Journal of Clinical Pharmacology·D C Brown, J G Collier
Jan 1, 1974·European Journal of Clinical Pharmacology·R Schmidt, A Fanchamps
Dec 1, 1981·Cephalalgia : an International Journal of Headache·K EkbomE Waldenlind
Feb 1, 1982·British Journal of Clinical Pharmacology·P Tfelt-HansenJ J Ibraheem
Jun 1, 1982·British Journal of Clinical Pharmacology·P J LittleA Bobik
Jan 1, 1982·European Journal of Clinical Pharmacology·J J IbraheemP Tfelt-Hansen
Dec 1, 1980·The American Journal of Medicine·C Shim, M H Williams
Jan 1, 1957·Neurology·P BRAZIL, A P FRIEDMAN
Oct 20, 1960·The New England Journal of Medicine·J R GRAHAMH F GRAMM
Jan 25, 1964·British Medical Journal·J CROOKSW BRASS

❮ Previous
Next ❯

Citations

Jan 1, 1985·European Journal of Clinical Pharmacology·J J IbraheemP Tfelt-Hansen
Sep 1, 1993·European Journal of Obstetrics, Gynecology, and Reproductive Biology·A N de GrootT K Eskes
Jun 11, 2004·Clinical Neuropharmacology·F FerranteL M Cupini
Sep 22, 2006·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·A MayUNKNOWN EFNS Task Force
Jun 17, 2006·Cephalalgia : an International Journal of Headache·E Laudon MeyerC Marcus
May 1, 1974·The Journal of Pharmacy and Pharmacology·L Paalzow
Nov 10, 2007·Current Medical Research and Opinion·T A ArmerN Ramadan
Feb 1, 2003·Headache·Stephen D Silberstein, Douglas C McCrory
Feb 1, 1996·Cephalalgia : an International Journal of Headache·W J Meyler
Mar 1, 1985·Cephalalgia : an International Journal of Headache·E WaldenlindL Wetterberg
Nov 3, 2006·Expert Review of Neurotherapeutics·Arne May, Tim P Jurgens
Jul 1, 1986·Acta Neurologica Scandinavica·A A Krabbe
Aug 7, 2004·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Marc LindenbergJennifer B Dressman

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.